Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 5/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7678284 | 0.89 | MAPT (0.42) | L3MBTL1ALDH1A1MAPK1 | |
| SCHEMBL7678702 | 0.78 | MAOA (0.41) | L3MBTL1ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7676820 | 0.74 | HRH3 (0.37) | ALDH1A1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL1566658 | 0.66 | CYP3A4 (0.68) | L3MBTL1ALDH1A1SMN1; SMN2CYP3A4ALOX5 | |
| SCHEMBL7678128 | 0.63 | PTGS2 (0.59) | L3MBTL1ALDH1A1SMN1; SMN2CYP3A4MAPK1 | |
| SCHEMBL7682148 | 0.62 | MAOA (0.39) | ALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL3291219 | 0.60 | ALDH1A1 (0.66) | L3MBTL1ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| Methyl Alcohol SCHEMBL27399292 | 0.59 | CYP3A4 (0.61) | L3MBTL1ALDH1A1SMN1; SMN2CYP3A4ALOX5 | |
| SCHEMBL20474525 | 0.58 | ATM (0.57) | L3MBTL1ALDH1A1SMN1; SMN2CYP3A4ALOX5 | |
| SCHEMBL214448 | 0.58 | CES2 (0.61) | L3MBTL1ALDH1A1SMN1; SMN2CYP3A4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6455703-B2 | ADMINISTERING EFFECTIVE AMOUNT OF 1,3,6-TRIHYDRO-6-AZA-3-OXAPENTALEN-2-ONE DERIVATIVE TO THE PATIENT FOR INDUCING OR PROMOTING APOPTOSIS AND FOR ARRESTING UNCONTROLLED NEOPLASTIC CELL PROLIFERATION | CELL PATHWAYS, INC. | 2002-09-24 | — | — | US | disclosed |
| US-20010051651-A1 | 1,3,6,-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia | OSI PHARMACEUTICALS, INC. | 2001-12-13 | — | — | US | disclosed |
| US-6160003-A | 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia | CELL PATHWAYS, INC. (US) | 2000-12-12 | — | — | US | disclosed |
| US-5939417-A | 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia | CELL PATHWAYS INC (US) | 1999-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051651-A1 | 1,3,6,-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia | MALT1, VHL, CDKN1A | L3MBTL1 1764/4885ALDH1A1 208/4885NPC1 1644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.